Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRONASDAQ:ALKSNASDAQ:AXSMNASDAQ:SRRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$54.90-0.9%$45.51$21.02▼$58.40$4.38B-0.161.01 million shs1.10 million shsALKSAlkermes$29.33-1.5%$29.77$22.90▼$36.45$4.84B0.471.74 million shs1.74 million shsAXSMAxsome Therapeutics$102.89+1.3%$106.70$72.02▼$139.13$5.07B0.47677,064 shs650,414 shsSRRASierra Oncology$54.99$54.93$14.91▼$55.19$1.34B0.03931,731 shsN/ABeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics0.00%+2.50%+15.41%+21.41%+147.74%ALKSAlkermes0.00%-4.71%-7.39%-15.23%+20.11%AXSMAxsome Therapeutics0.00%-3.16%-5.04%-18.85%+35.35%SRRASierra Oncology0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKROAkero Therapeutics3.4852 of 5 stars3.51.00.04.71.31.70.0ALKSAlkermes4.7519 of 5 stars4.41.00.04.23.32.51.9AXSMAxsome Therapeutics4.6399 of 5 stars4.52.00.04.51.34.20.6SRRASierra OncologyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 3.00Buy$82.5050.27% UpsideALKSAlkermes 2.83Moderate Buy$40.0036.38% UpsideAXSMAxsome Therapeutics 3.06Buy$172.3367.49% UpsideSRRASierra Oncology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SRRA, AXSM, ALKS, and AKRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025ALKSAlkermesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$33.00 ➝ $42.006/12/2025AXSMAxsome TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$193.00 ➝ $186.006/10/2025AXSMAxsome TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$180.006/9/2025AXSMAxsome TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$153.00 ➝ $150.006/3/2025AXSMAxsome TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$185.005/28/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral ➝ Buy$45.005/27/2025AKROAkero TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$63.00 ➝ $64.005/22/2025AXSMAxsome TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$180.00 ➝ $180.005/14/2025AXSMAxsome TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025AKROAkero TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $78.005/13/2025ALKSAlkermesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/AALKSAlkermes$1.56B3.11$2.65 per share11.06$9.05 per share3.24AXSMAxsome Therapeutics$385.69M13.14N/AN/A$1.18 per share87.19SRRASierra Oncology$300K4,476.00N/AN/A$6.16 per share8.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$252.06M-$1.95N/AN/AN/AN/A-15.19%-13.97%8/8/2025 (Estimated)ALKSAlkermes$367.07M$2.0914.0321.411.8223.30%27.52%17.98%7/23/2025 (Estimated)AXSMAxsome Therapeutics-$287.22M-$5.77N/A36.49N/A-64.39%-272.80%-36.69%8/4/2025 (Estimated)SRRASierra Oncology-$94.66M-$6.77N/AN/AN/AN/A-111.88%-100.01%N/ALatest SRRA, AXSM, ALKS, and AKRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AKROAkero Therapeutics-$1.01$0.90+$1.91$0.90N/AN/A5/1/2025Q1 2025ALKSAlkermes$0.32$0.13-$0.19$0.13$307.53 million$306.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/AALKSAlkermesN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ASRRASierra OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0316.8016.80ALKSAlkermesN/A3.332.92AXSMAxsome Therapeutics3.482.031.96SRRASierra Oncology0.0221.2721.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/AALKSAlkermes95.21%AXSMAxsome Therapeutics81.49%SRRASierra Oncology99.30%Insider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.07%ALKSAlkermes4.40%AXSMAxsome Therapeutics22.30%SRRASierra Oncology44.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.72 million74.08 millionOptionableALKSAlkermes1,800164.90 million157.65 millionOptionableAXSMAxsome Therapeutics38049.24 million38.26 millionOptionableSRRASierra Oncology10924.42 million13.65 millionOptionableSRRA, AXSM, ALKS, and AKRO HeadlinesRecent News About These CompaniesGSK bolsters cancer pipeline with $1.9bn Sierra Oncology buyOctober 4, 2024 | pharmaphorum.comNew cancer treatment center breaks ground in ReddingSeptember 25, 2024 | actionnewsnow.comImplementation of a Novel Pathway to Integrate Palliative and Oncology Care for Patients With Acute Myeloid Leukemia in a Community HospitalSeptember 19, 2024 | ascopubs.orgNew regional cancer center in Redding is called the Sierra Pacific Regional Cancer CenterAugust 21, 2024 | actionnewsnow.comSierra Space eyes IPO market as it braces for a 'profound industrial revolution' in spaceApril 11, 2024 | msn.comSierra Space, valued at $5.3 billion, eyes IPO to 'accelerate the new space economy'April 11, 2024 | aol.comUsed 2021 GMC Sierra 2500 trucks for sale near meApril 5, 2024 | cars.comAnemia of InflammationMarch 26, 2024 | nejm.orgSierra Oncology Inc.February 21, 2024 | thestreet.comSierra Leone Airport, Sierra Leone, Sierra Leone [ SRK / ]February 15, 2024 | prokerala.com2014 GMC Sierra 1500 specs & colorsFebruary 6, 2024 | cars.comUsed 2014 GMC Sierra 1500 Denali trucks for sale near meJanuary 5, 2024 | cars.com2017 GMC Sierra 1500December 17, 2023 | motortrend.comSafety in Radiation Oncology (SAFRON)December 16, 2023 | iaea.org2024 GMC Sierra 2500HDNovember 24, 2023 | driving.caSierra deputies believe bear mauled woman after she diedNovember 20, 2023 | kcra.comSierra Coupon for OctoberNovember 9, 2023 | time.comCompare 6 trims on the 2021 GMC Sierra 1500October 31, 2023 | cars.comClario presents a three-part webinar series on oncology trial solutionsOctober 31, 2023 | galvnews.comFDA approves GSK's unique myelofibrosis treatment OjjaaraSeptember 18, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingChina Market Movers: MCHI, PDD, BIDU Show Bullish TrendsBy Gabriel Osorio-Mazilli | June 16, 2025View China Market Movers: MCHI, PDD, BIDU Show Bullish TrendsTariff Talks Advance, What Taiwan Semiconductor Can DeliverBy Gabriel Osorio-Mazilli | June 16, 2025View Tariff Talks Advance, What Taiwan Semiconductor Can DeliverSRRA, AXSM, ALKS, and AKRO Company DescriptionsAkero Therapeutics NASDAQ:AKRO$54.90 -0.50 (-0.90%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$55.26 +0.36 (+0.65%) As of 06/18/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Alkermes NASDAQ:ALKS$29.33 -0.44 (-1.48%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$29.79 +0.46 (+1.56%) As of 06/18/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Axsome Therapeutics NASDAQ:AXSM$102.89 +1.29 (+1.27%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$101.66 -1.22 (-1.19%) As of 06/18/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Sierra Oncology NASDAQ:SRRASierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
